Rofecoxib for rheumatoid arthritis

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 7, 2005, Pages

  Garner, Sarah E ^a   Fidan, Dogan ^b   Frankish, Ruth R ^a   Judd, Maria ^c   Towheed, Tanveer ^d   Tugwell, Peter ^e   Wells, George A ^f  

^a National Institute for Clinical Excellence   (United Kingdom)

^b Aventis Pharma Ltd   (United Kingdom)

^c Utilisation de la Recherche   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LACTONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SULFONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG APPROVAL; HUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE INHIBITORS; DRUG APPROVAL; HUMANS; LACTONES; NAPROXEN; RANDOMIZED CONTROLLED TRIALS; SULFONES;

EID: 18944402178     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003685.pub2     Document Type: Review

References (32)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid arthritis. The VIGOR trial. New England Journal of Medicine 2000;343(21):1520-1584.
2. Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q, et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clinical Therapeutics 1999;21(10):1688-1702.
3. Bjarnason I SGCReal. COX-2 specific inhibition with MK-096625 or 50 mg Q.D. does not increase intestinal permeability [abstract]. American journal of Gastroenterology 1998;93(9):1670-Abstract 246.
4. Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Alimentary Pharmacology & Therapeutics 1999;13(6):761-767.
5. Malmstrom K, Daniels S, Kotey P, Seidenberg B, Desjardins P. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. Clinical Therapeutics 1999;21(10):1653-1663.
6. Sigthrosson G, Crane R, Simon T, Hoover M, et al. Cox-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double-blind cross-over study comparing rofecoxib with placebo and indomethacin. GUT 2000;47:527-532.
7. 6 week placebo controlled study 137 patients (125mg rofecoxib, 175mg rofecoxib versus placebo). Centre for Drug Evaluation and Research (CDER017) plus extension.
8. Hawkey CJ, Laine L, Simon T, et al. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen or placebo: a multicentre, randomised, double blind study. Gut 2003;52(820-826).
9. Phase IIb dose finding study. 2 year duration, 634 patients comparing 25, 50 mg rofecoxib to naproxen, placebo. Details in Konstam 2001.
10. Phase III: domestic US 1 year duration, 909 patients. Comparing 12.5, 25, 50mg rofecoxib with naproxen, placebo. Details in Konstam 2001.
11. Phase III international study. 1058 enrolled, 1 year duration. Rofecoxib 25, 50mg compared to naproxen, placebo. Details in Konstam 2001.
12. Measurement of clinical outcome within clinical service. Ongoing study 01/06/1999.
13. Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of COX-2-selective inhibitors. American Journal of Nephrology 2001;21(1):1-15.
14. Collins R, Peto R, MacMahon S, et al. Blood presure, stroke and coronary disease, II: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838.
15. Daniels B, Seidenberg B. Cardiovascular safety profile of rofecoxib in controlled clinical trials. Arthritis & Rheumatism 1999;42(Suppl 9):S143-Abstract 435.
16. FDA Advisory Committee. Cardiovascular safety review of rofecoxib. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf.
17. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis and Rheumatism 1993;36:729-40.
18. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith D, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism 1995;38:727-35.
19. Jadad AR, Moore RA, Carrol D, Jenkinson C. Assessing the quality of reports of randomised controlled trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
20. Konstam M, Weir R, Reicin A, Shapiro D, et al. Cardiovascular thrombotic events in controlled clinical trials of rofecoxib. Circulation 2001;104:r15-r23.
21. OMERACT. Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials. J Rheumatol 1993;20:526-91.
22. Pincus T, Stein CM. ACR20: clinical or statistical significance?. Arthritis Rheum 1999;42(8):1572-6.
23. Rocha JL, Fernandez-Alonso. Acute tubulointerstitial nephritis associated wiht the selective COX II enzyme inhibitor rofecoxib. The Lancet 2001;357:9272.
24. Schulz KF, Chalmers I, Hayes RJ, Altman D. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408-12.
25. Silman A. Epidemiology and rheumatic diseases. In: Maddison P, Isenberg D, Woo P, Glass D editor(s). Oxford Textbook of Rheumatology. Oxford: Oxford University Press, 1998:811-28.
26. Siverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving NSAIDs: a randomised double-blind, placebo controlled trial. Annals of Internal Medicine 1995;123:241-49.
27. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284(10):1247-55.
28. Swan SK, Rudy DW, Lasseter KC, Ryan CF, et al. Effect of cyclooxygenase -2 inhibition on renal function in elderly persons receiving a low salt diet: a randomised controlled trial. Annals of Internal Medicine 2000;133(1):1-9.
29. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annual Review of Pharmacology & Toxicology 1998;38:97-120.
30. Wallberg-Jonsson S, Johansson H, Ohman ML. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. Journal of Rheumatology 1999;26:2562-2571.
31. Watson M, Brooks S, Kirwan J, Faulkner A. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. Cochrane Database of Systematic Reviews 2000, Issue 2.
32. Whelton A, Fort JG, Puma JA, et al. Cyclo-oxygenase-2 specific inhibitors and cardio-renal function: a randomised controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. American Journal of Therapeutics 2001;8.